Renal Cancer Drug Lenvatinib Meets Primary Endpoint

The phase II part of a phase I/II clinical trial (Study 205) of the anticancer agent lenvatinib mesylate (Eisai Co., Ltd.) in unresectable advanced or metastatic renal cell carcinoma (RCC) has met its primary endpoint.01/31/2015

Source: Kidney Cancer Association - January 31, 2015 Category: Cancer & Oncology Source Type: news